SEARCH HEALTH CONDITIONS BY ALPHABETS
Hypercalcemia of Malignancy
Medications for Hypercalcemia of Malignancy
About Hypercalcemia of Malignancy: Hypercalcemia of Malignancy is a excessive Quantity of calcium in the blood correlated with malignant tumors.
Drugs Used in the Treatment of Hypercalcemia of Malignancy
This set of medications come in some way associated with, or found at the treating this condition.
| Drug title | Rx / OTC | Pregnancy | CSA | Alcohol | Reviews | Rating | Popularity |
|---|---|---|---|---|---|---|---|
| Zometa | Rx | D | N | 3 reviews | 7.5 | ||
Generic title: zoledronic acid systemic Drug course: bisphosphonates For consumers: dose, interactions, and side effects For professionals: AHFS DI Monograph, Prescribing Information | |||||||
| Sensipar | Rx | C | N | Add review | 0.0 | ||
Generic title: cinacalcet systemic Drug course: calcimimetics For consumers: dose, interactions, and side effects For professionals: AHFS DI Monograph, Prescribing Information | |||||||
| dexamethasone | Rx | C | N | Add review | 0.0 | ||
Generic title: dexamethasone systemic Brand names: Dexamethasone Intensol, Dexpak Taperpak, De-Sone LA, Dxevo, HiDex...show all Drug category: glucocorticoids For consumers: dose, interactions, For professionals: a Z Drug Truth, AHFS DI Monograph, Prescribing Information | |||||||
| zoledronic acid | Rx | D | N | 4 reviews | 8.0 | ||
Generic title: zoledronic acid systemic Brand names: Zometa, Aclasta, Reclast Drug course: bisphosphonates For consumers: dose, interactions, For professionals: a Z Drug Truth, AHFS DI Monograph, Prescribing Information | |||||||
| Xgeva | Rx | X | N | Inch review | 1.0 | ||
Generic title: denosumab systemic Drug class: mixed bone resorption inhibitors For consumers: dose, interactions, and side effects For professionals: Prescribing Information | |||||||
| cinacalcet | Rx | C | N | Add review | 0.0 | ||
Generic title: cinacalcet systemic Brand title: Sensipar Drug course: calcimimetics For consumers: dose, interactions, For professionals: a Z Drug Truth, AHFS DI Monograph, Prescribing Information | |||||||
| pamidronate | Rx | D | N | Add review | 0.0 | ||
Generic title: pamidronate systemic Brand title: Aredia Drug course: bisphosphonates For consumers: dose, interactions, For professionals: a Z Drug Truth, AHFS DI Monograph, Prescribing Information | |||||||
| prednisone | Rx | C | N | Add review | 0.0 | ||
Generic title: prednisone systemic Drug course: glucocorticoids For consumers: dose, interactions, For professionals: a Z Drug Truth, AHFS DI Monograph, Prescribing Information | |||||||
| Aredia | Rx | D | N | Add review | 0.0 | ||
Generic title: pamidronate systemic Drug course: bisphosphonates For consumers: dose, interactions, and side effects For professionals: AHFS DI Monograph, Prescribing Information | |||||||
| Aclasta | Rx | D | N | Add review | 0.0 | ||
Generic title: zoledronic acid systemic Drug course: bisphosphonates For consumers: dose, interactions, and side effects | |||||||
| Reclast | Rx | D | N | Add review | 0.0 | ||
Generic title: zoledronic acid systemic Drug course: bisphosphonates For consumers: dose, interactions, and side effects For professionals: Prescribing Information | |||||||
| denosumab | Rx | X | N | 3 reviews | 2.7 | ||
Generic title: denosumab systemic Brand title: Xgeva Drug class: mixed bone resorption inhibitors For consumers: dose, interactions, For professionals: a Z Drug Truth, AHFS DI Monograph | |||||||
| Dexamethasone Intensol | Rx | C | N | Add review | 0.0 | ||
Generic title: dexamethasone systemic Drug course: glucocorticoids For consumers: dose, interactions, side effects | |||||||
| etidronate | Rx | C | N | Add review | 5.0 | ||
Generic title: etidronate systemic Drug course: bisphosphonates For consumers: dose, interactions, For professionals: a Z Drug Truth, AHFS DI Monograph, Prescribing Information | |||||||
| Dexpak Taperpak | Rx | C | N | Add review | 0.0 | ||
Generic title: dexamethasone systemic Drug course: glucocorticoids For consumers: dose, interactions, and side effects For professionals: AHFS DI Monograph, Prescribing Information | |||||||
| De-Sone LA | Rx | C | N | Add review | 0.0 | ||
Generic title: dexamethasone systemic Drug course: glucocorticoids For consumers: dose, interactions, side effects | |||||||
| Dxevo | Rx | C | N | Add review | 0.0 | ||
Generic title: dexamethasone systemic Drug course: glucocorticoids For consumers: dose, interactions, and side effects For professionals: Prescribing Information | |||||||
| HiDex | Rx | C | N | Add review | 0.0 | ||
Generic title: dexamethasone systemic Drug course: glucocorticoids For consumers: dose, interactions, and side effects For professionals: Prescribing Information | |||||||
Legend
| Rx | Prescription Only |
|---|---|
| OTC | On The Counter |
| Rx/OTC | Prescription or Over The Counter |
| Away Prizes | This drug might well not be approved by the FDA for the treatment of this condition. |
| Pregnancy Category | |
|---|---|
| A | sufficient and well-controlled studies have failed to present a risk to the embryo in the first trimester of pregnancy (and there is no evidence of risk in later trimesters). |
| B | Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no sufficient and well-controlled studies in pregnant women. |
| C | Animal reproduction studies have demonstrated an adverse effect on the fetus and there are no sufficient and well-controlled studies in humans, but potential benefits may warrant use in pregnant women despite potential risks. |
| D | There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may justify use in pregnant women despite potential risks. |
| X | Studies in animals or humans have demonstrated fetal abnormalities and/or there`s positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and also the risks involved in use in pregnant women clearly outweigh potential rewards. |
| N | FDA have not classified the drug. |
| Controlled Substances Act (CSA) Program | |
|---|---|
| N | Is not at the mercy of the Controlled Substances Act. |
| Inch | Has a high potential for misuse. Has no currently accepted medical use in treatment in the United States. There`s a lack of accepted safety for use under medical supervision. |
| 2 | Has a high potential for misuse. Includes a currently accepted medical use with severe restrictions or a currently accepted medical use in treatment in the United States. Abuse may cause acute emotional or physical dependence. |
| 3 | includes a potential for abuse less than those in schedules 1 and 2 two. Includes a currently accepted medical use in treatment in the United States. Abuse may lead to moderate or low physical dependence or high psychological dependence. |
| 4 | Has a minimal potential for abuse relative to those in program 3. It`s a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in program 3. |
| 5 | Has a minimal potential for abuse relative to those in program 4. Includes a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence. |
| Infection | |
|---|---|
| X | Interacts with Medication. |
Browse Treatment Plans
- A
- B
- C
- D
- E
- F
- G
- H
- that I
- J
- K
- L
- M
- N
- O
- P
- Q
- Runciman
- S
- T
- U
- V
- W
- X
- Y
- Z
Further info
Always consult your physician to ensure the information displayed on these pages relates to your circumstances.
Top USA Pharma Companies
Popular Categories
Easily find an affordable health insurance plan
